immunoglobulin light chain variable region fragment [Homo sapiens]/[Mus musculus]
(Synonyms: H2N-Leu-Leu-Ile-Tyr-Trp-Ala-Ser-Thr-Arg-OH ) 目录号 : GP10133
Immunoglobulin light chain fragment
![immunoglobulin light chain variable region fragment [Homo sapiens]/[Mus musculus] Chemical Structure](/media/struct/GP1/GP10133.png "immunoglobulin light chain variable region fragment [Homo sapiens]/[Mus musculus] Chemical Structure")
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Immunoglobulin light chain variable region fragment [Homo sapiens]/[Mus musculus] is a fragment (Leu-Leu-Ile-Tyr-Trp-Ala-Ser-Thr-Arg) on the variable region of the human and mouse immunoglobulin light chain.
Immunoglobulins (Ig) are the antigen recognition molecules of B cells. An Ig molecule is made up of 2 identical heavy chains and 2 identical light chains joined by disulfide bonds so that each heavy chain is linked to a light chain and the 2 heavy chains are linked together. On each of the light chain, there is one variable region and a constant region. The variable region is the most important for binding to antigens.
The antigen combining site of an antibody is made up of the variable regions of one light chain and one heavy chain. Within the variable regions, typically comprising 105-110 amino acids, some positions show more sequence variation than others. The variable fragments are the smallest fragment made from enzymatic cleavage of IgG and IgM class antibodies.
References:
1. Janeway CA, Jr et al. (2001). Immunobiology. (5th ed.). Garland Publishing. ISBN 0-8153-3642-X
2. Woof J, Burton D (2004). “Human antibody-Fc receptor interactions illuminated by crystal structures”. Nat Rev Immunol 4 (2): 89–99. doi :10.1038/nri1266. PMID 15040582.
3. Mattu T, Pleass R, Willis A, Kilian M, Wormald M, Lellouch A, Rudd P, Woof J, Dwek R (1998). “The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions”. J Biol Chem 273 (4): 2260–72. doi:10.1074/jbc.273.4.2260. PMID 9442070.
4. Roux K (1999). “Immunoglobulin structure and function as revealed by electron microscopy”. Int Arch Allergy Immunol 120 (2): 85–99. doi :10.1159/000024226. PMID 10545762.
5. Barclay A (2003). “Membrane proteins with immunoglobulin-like domains–a master superfamily of interaction molecules”. Semin Immunol 15 (4): 215–23. doi :10.1016/S1044-5323(03)00047-2. PMID 14690046 .
6. Putnam FW, Liu YS, Low TL (1979). “Primary structure of a human IgA1 immunoglobulin. IV. Streptococcal IgA1 protease, digestion, Fab and Fc fragments, and the complete amino acid sequence of the alpha 1 heavy chain”. J Biol Chem 254 (8): 2865–74. PMID 107164.
7. Huber R (1980). “Spatial structure of immunoglobulin molecules”. Klin Wochenschr 58 (22): 1217–31. doi :10.1007/ BF01478928 6780722.
| Cas No. | SDF | ||
| 别名 | H2N-Leu-Leu-Ile-Tyr-Trp-Ala-Ser-Thr-Arg-OH | ||
| Canonical SMILES | NC(CC(C)C)C(NC(CC(C)C)C(NC(C(C)CC)C(NC(CC1=CC=C(O)C=C1)C(NC(CC2=CNC3=C2C=CC=C3)C(NC(C)C(NC(CO)C(NC(C(O)C)C(NC(CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C54H83N13O13 | 分子量 | 1122.32 |
| 溶解度 | ≥ 112.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.891 mL | 4.4551 mL | 8.9101 mL |
| 5 mM | 0.1782 mL | 0.891 mL | 1.782 mL |
| 10 mM | 0.0891 mL | 0.4455 mL | 0.891 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。